Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Erik Rytter Ottosen is active.

Publication


Featured researches published by Erik Rytter Ottosen.


Bioorganic & Medicinal Chemistry Letters | 1997

Novel cyanoguanidines with potent oral antitumour activity

Charlotte Schou; Erik Rytter Ottosen; Hans Petersen; Fredrik Björkling; Scilla Latini; Pernille Vig Hjarnaa; Erik Bramm; Lise Binderup

4-Pyridyl cyanoguanidines with hydrophobic aromatic side chains showed potent antiproliferative activity in the human breast and lung cancer cell lines MCF-7, NYH and H460. In vivo, treatment with N-(6-chlorophenoxyhexyl)-N′-cyano-N″-4-pyridylguanidine (18, 20 mg/kg/day po.), gave a complete remission of tumours in a model of NYH inoculated nude mice.


Biochemical Pharmacology | 2000

Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine

Sara Ekelund; Gunnar Liminga; Fredrik Björkling; Erik Rytter Ottosen; Charlotte Schou; Lise Binderup; Rolf Larsson

CHS 828, a newly recognized pyridyl cyanoguanidine, has shown promising antitumor activity both in vitro and in vivo and is presently in early phase I clinical trial in collaboration with EORTC. In this study, the effects of CHS 828 and a series of analogues on extracellular acidification and cytotoxicity were compared with those of m-iodobenzylguanidine (MIBG) in human tumor cells. The extracellular acidification rate was measured using the Cytosensor microphysiometer, and determination of cytotoxicity and proliferation was [(14)C] performed by the fluorometric microculture cytotoxicity assay (FMCA) and measurement of [(14)C]thymidine and leucine uptake. CHS 828 significantly increased the acidification rate during the first 15-24 hr in a concentration-dependent manner. This effect was abolished by removal of glucose from the medium, substituted with 10 mM of pyruvate, indicating stimulated glycolysis as the source of the increased acidification rate. However, CHS 828 induced cytotoxicity at concentrations well below those that affected the rate of acidification; when a series of closely related pyridylguanidine analogues were tested and compared, no apparent relationship between cytotoxicity and acidification could be discerned. Furthermore, comparable increases in the acidification rate were evident in one subline with high-grade resistance to the cytotoxic actions of CHS 828. The results indicate that CHS 828 may share the inhibitory actions of MIBG on mitochondrial respiration with a subsequent increase in glycolysis and acidification rate. However, this mechanism of action appears neither necessary nor sufficient to fully explain the cytotoxic actions of CHS 828 in human tumor cells, actions which remain to be mechanistically clarified.


Journal of Medicinal Chemistry | 2003

Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity

Erik Rytter Ottosen; Morten Dahl Sørensen; Fredrik Björkling; Tine Skak-Nielsen; Marianne Scheel Fjording; Helle Aaes; Lise Binderup


Archive | 2010

HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS

Simon Feldbaek Nielsen; Daniel Rodriguez Greve; Carsten Ryttersgaard; Gunnar Grue-Sørensen; Erik Rytter Ottosen; Tina Dahlerup Poulsen; Søren Christian Schou; Anthony Murray


Archive | 1998

Cyanoguanidines as cell proliferation inhibitors

Charlotte Schou; Erik Rytter Ottosen


Archive | 2004

Novel aminobenzophenone compounds

Erik Rytter Ottosen; Anne Marie Horneman; Xifu Liang; Soeren Christian Schou; Sophie Elisabeth Havez; Thomas Peter Sabroe


Archive | 2000

Aminobenzophenones as inhibitors of il-1beta and tnf-alpha

Erik Rytter Ottosen


Archive | 1998

Aminobenzophenones as inhibitors of interleukin and tnf

Erik Rytter Ottosen; Schneur Rachlin


Archive | 2005

Triazole substituted aminobenzophenone compounds

Erik Rytter Ottosen


Archive | 2017

composto, composição farmacêutica, uso de um composto, e, método para a prevenir tratar ou melhorar doenças do sistema imune

Anthony Murray; Carsten Ryttersgaard; Daniel Rodriguez Greve; Erik Rytter Ottosen; Gunnar Grue-Sørensen; Simon Feldbaek Nielsen; Søren Christian Schou; Tina Dahlerup Poulsen

Collaboration


Dive into the Erik Rytter Ottosen's collaboration.

Researchain Logo
Decentralizing Knowledge